Focus on Vaccine Development 4 – Virus: Vaccine and VLP Characterization with Nano-particle Tracking Analysis (NTA)

The last webinar in this series will elaborate on the value of Nanoparticle Tracking Analysis (NTA) to the development of vaccines, including the characterization of VLPs (several Virus Like Particles being developed as vaccines to COVID19). 

More than a simple particle size analysis, the ability to rapidly make total (not just infective) particle concentration measurements is essential to vaccine developers looking to optimize the purity and shelf-life of their product. 

NTA allows all particles in the preparation to be visualized and sized, generating directly applicable information about nano-particle content in a shorter time than would be available through conventional TCID50 or plaque assays. For instance, the presence of larger particles could represent either non-viral cell debris from the cell culture process or aggregates of virus particles containing many individual virions. In either case, such aggregates/contaminants represent a possible problem to the manufacturer – this webinar will demonstrates how the Malvern Panalytical NanoSight system helps them devise a solution.Register for event


Date:May 20 2020 – May 20 2020Time:10:30 – 11:30
(GMT-05:00) Eastern [US & Canada]Event type:Webinar – LiveLanguage:EnglishTechnology:Nanoparticle Tracking AnalysisIndustry:Pharmaceuticals


Jonathan Mehtala Ph.D. – Application Scientist Nanosight

More information

  • Who should attend?
    – Scientists and project leaders in industry and academia working on the discovery and development of protein-based vaccines and therapeutics.

Register for event